Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists.
Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists.
复制标题
DOI：
10.1155/2011/897894
复制
发表时间：
2011
影响因子：
3.3
通讯作者：
Hontecillas R
中科院分区：
文献类型：
--
作者：
Bassaganya-Riera J;Guri AJ;Hontecillas R
肥胖及其相关合并症的患病率在美国和世界范围内已增长到流行病的比例。 因此，开发针对这些广泛和使人衰弱的疾病的安全有效的治疗方法是重要和及时的。通过几类药物激活过氧化物酶体增殖物激活受体（PPARs）α、γ和δ可以预防或治疗多种代谢和炎症性疾病，包括II型糖尿病（T2D）。因此，PPARs代表了开发用于广泛的衰弱和广泛的肥胖相关疾病和病症的新的和更好的治疗的重要分子靶标。然而，可用的PPAR γ激动剂药物如文迪雅具有显著的不良副作用，包括体重增加、液体潴留、肝毒性和充血性心力衰竭。合成的PPAR γ激动剂的替代方案是发现和开发天然存在的和更安全的营养品，其可以是双重或泛PPAR激动剂。本文综述了脱落酸（阿坝）、石榴酸（普阿）和梓酸（CAA）这三种植物源性过氧化物酶体增殖物激活物受体激动剂在慢性炎症和代谢性疾病及紊乱的预防和治疗中的健康效应。
The prevalence of obesity and its associated comorbidities has grown to epidemic proportions in the US and worldwide. Thus, developing safe and effective therapeutic approaches against these widespread and debilitating diseases is important and timely. Activation of peroxisome proliferator-activated receptors (PPARs) α, γ, and δ through several classes of pharmaceuticals can prevent or treat a variety of metabolic and inflammatory diseases, including type II diabetes (T2D). Thus, PPARs represent important molecular targets for developing novel and better treatments for a wide range of debilitating and widespread obesity-related diseases and disorders. However, available PPAR γ agonistic drugs such as Avandia have significant adverse side effects, including weight gain, fluid retention, hepatotoxicity, and congestive heart failure. An alternative to synthetic agonists of PPAR γ is the discovery and development of naturally occurring and safer nutraceuticals that may be dual or pan PPAR agonists. The purpose of this paper is to summarize the health effects of three plant-derived PPAR agonists: abscisic acid (ABA), punicic acid (PUA), and catalpic acid (CAA) in the prevention and treatment of chronic inflammatory and metabolic diseases and disorders.